Pulmonx Corporation develops and commercializes medical technologies for the treatment of obstructive lung diseases, particularly emphysema. Its primary product is the Zephyr® Valve, an implantable device that facilitates bronchoscopic lung volume reduction without surgery. The company also offers the StratX® Lung Analysis Reports, a cloud-based service for assessing lung conditions, and the Chartis® Pulmonary Assessment System, which evaluates airflow and pressure in the lungs. Pulmonx operates in various global markets, including Europe, the United States, Australia, Asia, and Latin America.
